Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neuroradiology
Published in: Neuroradiology 12/2017

01-12-2017 | Diagnostic Neuroradiology

Prospective intraindividual comparison of gadoterate and gadobutrol for cervical and intracranial contrast-enhanced magnetic resonance angiography

Authors: Philip Hoelter, Stefan Lang, Marina Weibart, Manuel Schmidt, Michael F. X. Knott, Tobias Engelhorn, Marco Essig, Stephan Kloska, Arnd Doerfler

Published in: Neuroradiology | Issue 12/2017

Login to get access

Abstract

Purpose

Gadobutrol (GB) is reported to provide improved relaxivity and concentration compared to gadoterate (GT). This study was designed to intraindividually compare quantitative and qualitative enhancement characteristics of GB to GT in cervicocranial magnetic resonance angiography (MRA) of patients with cerebrovascular disease (CVD).

Methods

Patients (n = 54) with CVD underwent two identical contrast-enhanced magnetic resonance angiography (CE-MRA) examinations of the cervical and intracranial vasculature in randomized order, using GB and GT in equimolar dose. Signal-to-noise ratios (SNR) and contrast-to-noise ratios (CNR) were obtained by two independent neuroradiologists, blinded to the applied contrast agents. Qualitative assessment was performed using a three-point scale with a focus on M1/M2 segments.

Results

One thousand and twenty-six vessel segments were analyzed. GB revealed a significantly higher SNR (p = 0.032) and CNR (p = 0.031) in all vessel segments. GB featured a significantly higher SNR and CNR in thoracic (p = 0.022; p = 0.016) and cervical vessels (p = 0.03; p = 0.038), as well as in the posterior circulation (p = 0.012; p = 0.005). In blinded qualitative assessment, overall preference was given to GB (p = 0.02), showing a significant better delineation of the M1/M2 segments (p = 0.041).

Conclusion

Compared to GT, the use of GB results in a significantly higher SNR and CNR in cervical and cerebral CE-MRA, leading to a better delineation of the intracranial vasculature. Present results underline the potential of GB for improved CE-MRA assessment of vasculature in CVD patients.
Literature
1.
2.
UK-I JM, Young V, Gillard JH (2009) Carotid-artery imaging in the diagnosis and management of patients at risk of stroke. Lancet Neurol 8(6):569–580CrossRef
3.
Fairhead JF, Mehta Z, Rothwell PM (2005) Population-based study of delays in carotid imaging and surgery and the risk of recurrent stroke. Neurology 65(3):371–375CrossRefPubMed
4.
Herborn CU, Lauenstein TC, Ruehm SG, Bosk S, Debatin JF, Goyen M (2003) Intraindividual comparison of gadopentetate dimeglumine, gadobenate dimeglumine, and gadobutrol for pelvic 3D magnetic resonance angiography. Investig Radiol 38(1):27–33CrossRef
5.
Goyen M, Herborn CU, Vogt FM et al (2003) Using a 1 M Gd-chelate (gadobutrol) for total-body three-dimensional MR angiography: preliminary experience. J Magn Reson Imaging: JMRI 17(5):565–571CrossRefPubMed
6.
Degnan AJ, Gallagher G, Teng Z, Lu J, Liu Q, Gillard JH (2012) MR angiography and imaging for the evaluation of middle cerebral artery atherosclerotic disease. AJNR Am J Neuroradiol 33(8):1427–1435CrossRefPubMed
7.
Giesel FL, Mehndiratta A, Essig M (2010) High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review. Eur Radiol 20(10):2461–2474CrossRefPubMed
8.
Altun E, Semelka RC, Cakit C (2009) Nephrogenic systemic fibrosis and management of high-risk patients. Acad Radiol 16(7):897–905CrossRefPubMed
9.
Shen Y, Goerner FL, Snyder C et al (2015) T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T. Investig Radiol 50(5):330–338CrossRef
10.
Tombach B, Heindel W (2002) Value of 1.0- M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol 12(6):1550–1556CrossRefPubMed
11.
Scott LJ (2013) Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children. Clin Drug Investig 33(4):303–314CrossRefPubMed
12.
Kramer H, Runge VM, Naul LG, Loynachan AT, Reiser MF, Wintersperger BJ (2010) Brain MRI with single-dose (0.1 mmol/kg) Gadobutrol at 1.5 T and 3 T: comparison with 0.15 mmol/kg gadoterate meglumine. AJR. Am J Roentgenol 194(5):1337–1342CrossRef
13.
Saake M, Langner S, Schwenke C et al (2016) MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T. Eur Radiol 26(3):820–828CrossRefPubMed
14.
Haneder S, Attenberger UI, Schoenberg SO, Loewe C, Arnaiz J, Michaely HJ (2012) Comparison of 0.5 M gadoterate and 1.0 M gadobutrol in peripheral MRA: a prospective, single-center, randomized, crossover, double-blind study. J Magn Reson Imaging: JMRI 36(5):1213–1221CrossRefPubMed
15.
Pennekamp W, Roggenland D, Hering S et al (2011) Intra-individual, randomised comparison of the MRI contrast agents gadobutrol and gadoterate in imaging the distal lower limb of patients with known or suspected osteomyelitis, evaluated in an off-site blinded read. Eur Radiol 21(5):1058–1067CrossRefPubMed
16.
Kramer JH, Arnoldi E, Francois CJ et al (2013) Dynamic and static magnetic resonance angiography of the supra-aortic vessels at 3.0 T: intraindividual comparison of gadobutrol, gadobenate dimeglumine, and gadoterate meglumine at equimolar dose. Investig Radiol 48(3):121–128CrossRef
17.
Jauch EC, Saver JL, Adams HP Jr et al (2013) Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44(3):870–947CrossRefPubMed
18.
Townsend TC, Saloner D, Pan XM, Rapp JH (2003) Contrast material-enhanced MRA overestimates severity of carotid stenosis, compared with 3D time-of-flight MRA. J Vasc Surg 38(1):36–40CrossRefPubMed
19.
Achterberg S, Cramer MJ, Kappelle LJ et al (2010) Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study. Eur J Cardiovasc Preven Rehab 17(4):424–430CrossRef
20.
Attenberger UI, Runge VM, Morelli JN, Williams J, Jackson CB, Michaely HJ (2010) Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T. J Magn Reson Imaging: JMRI 31(3):549–555CrossRefPubMed
21.
Szucs-Farkas Z, Froehlich JM, Ulrich M et al (2008) 1.0-M gadobutrol versus 0.5-M gadoterate for peripheral magnetic resonance angiography: a prospective randomized controlled clinical trial. J Magn Reson Imaging: JMRI 27(6):1399–1405CrossRefPubMed
22.
Fink C, Bock M, Kiessling F et al (2004) Time-resolved contrast-enhanced three-dimensional pulmonary MR-angiography: 1.0 M gadobutrol vs. 0.5 M gadopentetate dimeglumine. J Magn Reson Imaging: JMRI 19(2):202–208CrossRefPubMed
23.
Gutberlet M, Spors B, Grothoff M et al (2004) Comparison of different cardiac MRI sequences at 1.5 T/3.0 T with respect to signal-to-noise and contrast-to-noise ratios—initial experience. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 176(6):801–808CrossRefPubMed
24.
Wen H, Denison TJ, Singerman RW, Balaban RS (1997) The intrinsic signal-to-noise ratio in human cardiac imaging at 1.5, 3, and 4 T. J Magn Reson 125(1):65–71CrossRefPubMedPubMedCentral
Metadata
Title
Prospective intraindividual comparison of gadoterate and gadobutrol for cervical and intracranial contrast-enhanced magnetic resonance angiography
Authors
Philip Hoelter
Stefan Lang
Marina Weibart
Manuel Schmidt
Michael F. X. Knott
Tobias Engelhorn
Marco Essig
Stephan Kloska
Arnd Doerfler
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Neuroradiology / Issue 12/2017
Print ISSN: 0028-3940
Electronic ISSN: 1432-1920
DOI
https://doi.org/10.1007/s00234-017-1922-z

Other articles of this Issue 12/2017

Neuroradiology 12/2017 Go to the issue

Interventional Neuroradiology

Flow diverter treatment of cerebral blister aneurysms

Interventional Neuroradiology

Clinical and angiographic outcomes in patients with intracranial aneurysms treated with the pipeline embolization device: intra-procedural technical difficulties, major morbidity, and neurological mortality decrease significantly with increased operator experience in device deployment and patient management

Functional Neuroradiology

Disease stage-dependent relationship between diffusion tensor imaging and electrophysiology of the visual system in a murine model of multiple sclerosis

Interventional Neuroradiology

In vitro, contrast agent-based evaluation of the influence of flow diverter size and position on intra-aneurysmal flow dynamics using syngo iFlow

Review

High-resolution vessel wall MRI for the evaluation of intracranial atherosclerotic disease

Diagnostic Neuroradiology

Quantitative susceptibility mapping of the motor cortex: a comparison of susceptibility among patients with amyotrophic lateral sclerosis, cerebrovascular disease, and healthy controls